Contraceptive Shortage Hits South Africa After Aspen Manufacturing Disruption
South Africa is currently experiencing a shortage of oral contraceptives following production challenges at Aspen Pharmacare’s manufacturing facilities, according to the Department of Health and reports from local pharmacy chains.
The disruption has affected several widely used state-subsidised contraceptives, including Triphasil, Nordette, and Microval, which are distributed through public clinics and private pharmacies across the country. As a result, many women have reported difficulty accessing their regular contraceptive medication.
The Department of Health confirmed that the shortages are linked to manufacturing setbacks at Aspen Pharmacare, a major supplier of pharmaceutical products in South Africa. The company’s production issues have impacted its ability to meet national demand, leading to supply constraints in both the public and private healthcare sectors.
According to the department, the situation highlights ongoing vulnerabilities within the country’s healthcare supply chain, which is often dependent on a limited number of manufacturers. Officials noted that disruptions can also be influenced by factors such as inaccurate demand forecasting, supplier production limitations, and delays in provincial procurement payments.
A department spokesperson explained that the shortages were primarily caused by manufacturing challenges at Aspen’s local operations, which affected the availability of several essential products.
Pharmacy group Clicks also confirmed the shortage, stating that Aspen had informed them of supply constraints affecting certain oral contraceptive brands. The company added that alternative products may be available for affected patients while supply stabilisation efforts continue.
In response to the disruption, Aspen Pharmacare has reportedly requested approval to source alternative contraceptive brands from other manufacturers. The Department of Health has approved this measure as part of efforts to reduce pressure on the supply chain and restore availability.
Aspen has since stated that it is working to expedite alternative supply arrangements and continues to prioritise deliveries to the public healthcare sector, with private sector distribution expected to follow.
Health authorities say the introduction of alternative brands has already begun to ease pressure on supply, with a more stable recovery in the availability of oral contraceptives expected toward the end of July.
While the situation is expected to improve in the coming weeks, the shortage has raised broader concerns about the resilience of South Africa’s pharmaceutical supply system and the risks associated with reliance on a limited number of suppliers.
Healthcare experts warn that such disruptions can have a significant impact on public health services, particularly for women who rely on consistent access to contraceptive medication for family planning and medical needs.
The Department of Health has urged affected individuals to consult healthcare providers or local clinics for available alternatives during the shortage period.
Authorities say monitoring and coordination efforts are ongoing to ensure supply levels return to normal as quickly as possible.